Document is current
Any future updates will be listed below
-
Authors
Stokx, Jocelijn
Hendrickx, Anne
Veliste, Kärt
Brouns, Chiara
Scheffler, Sandra
Schoch, Goentje-Gesine
Slapsak, Maja
Macken, Evelyn
Walter, Patrick
Kanga-Tona, Thomas
Barjesteh van Waalwijk van Doorn-Kh, Sahar https://orcid.org/0000-0003-1239-9867
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 18 March 2026
First Online: 16 April 2026
Declarations
:
: This study does not involve human subjects, and under 45 CFR §46.102(f), was not submitted for institutional review board approval and did not require informed consent.
: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani received research funding from Horizon Europe Cancer Mission, EC grant agreement no. 101104269 (PRIME-ROSE) and Joint Action for Personalised Cancer Medicine (JA-PCM), financed by EU4Health (grant no. 101233450). All authors have no financial conflicts of interest related to this manuscript.
: All authors were involved in the selection of medicines and study design. A representative from each country provided the relevant country-specific data. JS and AH curated the data, conducted the analysis, and wrote the first draft of the manuscript. TKT assisted with the analysis and coordinated the study across countries. All authors reviewed and approved the final version.
